iRhythm's Strong Q2 Earnings and Vital Connect Acquisition: A Sign of Growth
iRhythm's Q2 earnings beat and acquisition of Vital Connect signal promising growth in wearable health tech.
Eli Lilly's Next-Gen Weight-Loss Drug Filing: A Game Changer for Investors
Eli Lilly's FDA filing for a new weight-loss drug could reshape the market landscape and challenge competitors like Novo Nordisk.
NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine
NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling significant market potential.
Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications
Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentiment remains cautious.
Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments
Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering potential revenue growth.
Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol, a potential Starga…
Moderna's Groundbreaking mRNA Flu Vaccine Approval: A New Chapter in Vaccination
Moderna's mFLUSIVA, the first FDA-approved mRNA flu vaccine, is set to reshape the vaccination landscape and boost investor confidence.
Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment
Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market landscape.
Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors
Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond COVID-19.
Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA filing.
Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impact its stock.